BIN1 and non-small cell lung carcinoma: These findings open the way for more effective immunotherapies for NSCLC treatment based on reactivation of BIN1, which is able to reverse immune escape mediated by PD-L1 by inactivating MYC and EGFR/MAPK networks [71].